As a Data Scientist at Recursion Pharmaceuticals, you sit at the exciting intersection of advanced computational science, artificial intelligence, and industrialized drug discovery. Your work directly drives the refinement of the Recursion OS, helping decode complex biological and chemical datasets to accelerate the discovery of life-changing medicines. You will build and scale high-impact systems, turning massive arrays of experimental and proprietary data into structured insights that fuel automated scientific reasoning and machine learning frameworks.
The impact of this role is profound and foundational to the company's mission. You will partner closely with cross-functional teams including machine learning engineers, wet-lab biologists, and medicinal chemists to design context retrieval strategies, manage biological knowledge graphs, and develop agent-driven AI workflows. Whether you are optimizing vector representations for large-scale language model deployments or engineering data pipelines that ingest and harmonize public and private biomedical resources, your technical contributions enable automated systems to reason about disease biology with unprecedented scale and precision.
Expect an environment that demands rigorous scientific thinking alongside production-grade engineering excellence. Recursion Pharmaceuticals operates at a scale where traditional bioinformatics methods must be reimagined to leverage high-performance computing architectures and cutting-edge GenAI ecosystems. Success in this position requires a rare blend of deep domain knowledge in biology or chemistry, sophisticated data manipulation skills, and the pragmatism needed to translate complex prototypes into robust, production-grade workflows.
Recruiter Screening
reportedWhoever runs this call is usually not a practitioner. They take notes, and a hiring manager skims those notes later, so the real question is whether your work survives being written down by someone outside the field. Test every project sentence against that: could a non-specialist repeat it correctly without knowing what a propensity score is? Carry a plain-language version of each project and one reason you want this particular role that you could not copy onto another application. Vagueness at this stage reads as inexperience, even when the underlying work was genuinely deep.
What to demonstrate
- Whether a non-specialist can restate your projects accurately, since their paraphrase is what reaches the hiring manager
- Whether your reason for wanting the role points at the work itself rather than the company's reputation
- Whether your language signals the level being screened for: what you decided yourself versus what you were handed
How to prepare
- Write a two-sentence, jargon-free version of each major project: the question nobody could answer, and the decision your work changed. Read it to someone outside data and have them repeat it back
- Point your 'why this role' answer at something concrete in the job description or the product surface you would be working on, and keep it to two sentences
- Have two questions ready about measurement: which metric the team is held to, and who acts on an analysis once it lands
Hiring Manager Discussion
reportedMuch of this round runs on your own history, but the manager is not collecting a project list. They are working out what it is like when something goes wrong on your watch: how late the bad news tends to arrive, and whether a number you hand over has been checked by anyone including you. That is why the strongest material is a project where you can describe the part that did not work and what it cost. A result you cannot take full responsibility for, however clean, gives them nothing to trust you with afterwards.
What to demonstrate
- Whether you volunteer the limits of a result you are proud of, or wait to be pushed onto them
- How errors surfaced in your past work, and whether you or somebody else found them
- Whether the scope you claim matches the level of detail you can still produce about it
- What you did the first time a stakeholder acted on something of yours that turned out to be wrong
How to prepare
- Rebuild one headline figure from memory down to the join and the filter, so a question about the denominator does not stall the conversation
- For each project you raise, write the sentence you would say to someone who had already acted on a number that later turned out wrong
- Mark which parts of a project were yours and which belonged to other people, and state that boundary yourself before anyone asks
Technical Evaluations
reportedThis round decides whether someone can hand you a schema and a question and trust the number that comes back. Correctness under a clock is the bar, not clever syntax. The habit that separates strong from weak answers is checking the grain: after every join, know how many rows you expect and whether the count moved. Most wrong answers in this format are not wrong logic, they are a fan-out from a key that turned out not to be unique, or a filter applied before an aggregate when it belonged after. Say what you expect before you run it.
What to demonstrate
- Whether your row counts survive each join, and whether you notice on your own when they do not
- Deliberate handling of rows that fail to match, including whether the question needs an inner join or a left join with the non-matches kept and counted
- Whether NULLs are treated on purpose, given that a NULL compares equal to nothing and that COUNT of a column skips it
- Reaching a defensible answer inside the window instead of a refined one after it
How to prepare
- Take a two-table schema, write a join that fans out on purpose, then fix it by collapsing the many-side to one row per key before joining. Repeat until the fix is reflex rather than recall.
- Write a funnel as one query and print the distinct user count at each stage, then confirm each stage is a subset of the one above it rather than assuming it
- Do a few timed runs in a plain text box with no autocomplete and no formatter, since assessment editors often have neither
Panel Loop
reportedWhere a loop includes a partner from outside the data team, that conversation usually carries the same weight as the technical ones and gets the least preparation. The person opposite you will not follow a derivation and does not need to. They are working out whether having you involved would make their decisions better or slower. The failure mode is not being too technical. It is answering a question about a decision with a description of your method, leaving the translation to them. What they carry into the debrief is the sentence you handed them, not the analysis underneath it.
What to demonstrate
- Whether a statistical result arrives as something the partner could act on, with the one caveat that would change their decision kept and the rest left out
- Whether you can state what you need from their side, in their terms: instrumentation that does not exist yet, a definition they own, or a holdout they have to agree to
- Whether uncertainty is given as a range someone can plan against, rather than as hedging that invites them to ignore the result
- Whether you ask what decision is actually on the table before explaining anything
How to prepare
- Take a result you know well and write the version for someone who stops reading after one sentence, then the three-minute version, and check the short one is not the long one with the qualifications stripped out
- For a past project, list everything you asked a non-technical partner for and how you phrased it, then rewrite each ask so it names what goes unmeasured without it
- Practise saying where a result does not apply, out loud, in one sentence that a partner could repeat accurately to someone else
PracHub editorial advice for the preparation topics above.
Ignoring clustering by provider, facility, or site
Patients within a provider panel, and subjects within a trial site, are correlated on both case mix and practice pattern. Standard errors computed as if observations were independent are too narrow by roughly the design effect, 1 + (m - 1) * ICC, where m is the average cluster size. With 50 patients per provider and an intracluster correlation of only 0.02, variance is understated by about a factor of two, which manufactures significant provider differences out of noise. Cluster-robust errors or a random intercept per provider, and cluster-level randomisation when you design the test, are the corrections.
Rates built on member counts rather than exposure
Members join and leave mid-period, so dividing events by distinct members mixes a person covered for 30 days with one covered for 365. New joiners also have artificially low observed utilisation because their claims have not arrived yet and because care takes time to initiate. Denominators must be member-months or member-years, and comparative quality measures usually need a continuous-enrolment requirement with an explicit allowable gap, stated in days.
Reaching for a model before the target metric exists
Before naming an algorithm, write down the label, the prediction time, and the action that changes when the score crosses a threshold. If you cannot say what decision the output drives, any modelling choice is guesswork dressed up as method.
Optimising accuracy on a heavily imbalanced target
State the base rate first, then choose the metric from the relative cost of a false positive against a false negative: precision and recall at the operating threshold, PR-AUC, or expected cost. At a 1 percent positive rate, predicting the majority class for everyone scores 99 percent accuracy and is worthless.
Choose a category, try a prompt, then open its approach, worked solution or follow-up when you need it.
Explain the difference between false discovery rate control and family…
Explain the difference between false discovery rate control and family-wise error rate correction in high-throughput biological screening.
Approach
- Quantify uncertainty explicitly rather than reporting a point estimate alone.
- Write down the assumption the method needs before you use the method.
- Translate the result into the decision it informs, in one plain sentence.
Follow-up
- What sample size would you need to detect an effect half this size?
- Which assumption here is most likely to be violated in practice?
What are the most common experimentation pitfalls you encounter when r…
What are the most common experimentation pitfalls you encounter when running concurrent offline model evaluations?
Approach
- Say how the offline result would be validated online before it is trusted.
- Frame the prediction: the label, the moment of prediction, and the action it triggers.
- Set a baseline first, so any model has something honest to beat.
Follow-up
- Where could label leakage enter this setup?
- What would you monitor after launch to know the model is still valid?
Build a claims lag triangle and complete recent months
medical_claim_line has claim_id, claim_version, frequency_code, service_start_date, paid_date, allowed_amount, claim_status. Using 24 fully mature incurred months, build a development triangle of allowed dollars by incurred month and payment lag in whole months, derive cumulative completion factors by chain ladder, then estimate ultimate allowed for the three most recent incurred months at a stated paid-through date. Deduplicate to surviving claim versions before building the triangle. Return incurred_month, paid_to_date, completion_factor, estimated_ultimate.
Approach
- Deduplicate to surviving claim versions and keep paid lines first. A triangle built on all versions develops on adjustment churn rather than on payment timing, and replacements arrive late, so the distortion concentrates in exactly the tail you are trying to estimate.
- Compute lag as a whole-month difference between incurred month and paid month, not as day difference divided by 30. Ragged month lengths otherwise shuffle identical claims between lag buckets depending on which month they fall in.
- Pivot to incurred_month by lag, cumulate along lag, then form age-to-age factors as the ratio of the column L+1 total to the column L total, summed over incurred months mature enough to have both. Volume weighting is the chain ladder; a simple mean of per-month ratios lets one low-volume month dominate the factor.
- Chain the age-to-age factors from each lag to ultimate and invert: completion factor at lag L is the reciprocal of the product of factors from L onward. Apply as estimated_ultimate = paid_to_date / completion_factor.
- State the assumption you have just made, which is that the development pattern is stable. It is not, after a claims-system migration, a network change or a processing backlog, and the most recent month's factor is the least reliable because it rests on the fewest observations while carrying the largest adjustment.
Worked solution 35 min
- Deduplicate to surviving versions, drop voids, keep claim_status 'paid', and derive incurred_month from service_start_date and paid_month from paid_date.
- lag = (paid_month.year - incurred_month.year) x 12 + (paid_month.month - incurred_month.month); drop negative lags and investigate them separately.
- Pivot to a triangle of summed allowed_amount, cumulate along the lag axis, and mask cells past the paid-through date so no cell contains a future payment.
- Compute volume-weighted age-to-age factors per lag over the mature rows, then chain them into cumulative completion factors.
- Apply the factor for each recent month's current maturity to its paid_to_date and return the four columns.
Follow-up
- A processing backlog means the last two months developed slower than history. What does your estimate do, and how would you detect that before reporting?
- Pharmacy, professional and inpatient facility develop on different clocks. How do you split the triangle, and what breaks if the service mix shifts?
- What happens to a PMPM series if someone reports an unadjusted recent month, and in which direction does the error point?
Given a table of compound testing results, how would you rank compound…
Given a table of compound testing results, how would you rank compounds within each assay category using advanced grouping and ranking functions?
Approach
- Check whether any join is one-to-many before aggregating, or the sums inflate.
- Say which table is the grain you start from, and join outward from it.
- State the window function and its partition and ordering out loud before writing it.
Follow-up
- How does the query change if the join becomes one-to-many?
- What breaks if events arrive late or out of order?
How would you use SQL window functions to track consecutive experiment…
How would you use SQL window functions to track consecutive experimental assay failures over time for a specific molecular target?
Approach
- Check whether any join is one-to-many before aggregating, or the sums inflate.
- State the window function and its partition and ordering out loud before writing it.
- Compute rates by summing numerator and denominator separately, never by averaging rates.
Follow-up
- How would you verify this result without re-running the same query?
- How does the query change if the join becomes one-to-many?
Report site activation to first randomization without hiding non-enrollers
study_site holds one row per (study_id, site_id): site_activation_date, which is NULL for a site selected but never activated, and site_status. study_subject_visit holds subject_visit_id, study_id, site_id, subject_id, randomization_ts (NULL for screen failures), visit_name, visit_number, actual_visit_date and visit_status, with one row per subject per protocol visit, so randomization_ts repeats across every visit of a randomized subject and a site that has screened nobody has no rows there at all. For one study_id and a stated data cut date, return per activated site the activation date, the first randomization_ts and the days between them, with activated sites that have randomized nobody still present. Add a study-level summary giving median days to first randomization and the share of activated sites with no randomization by day 90.
Approach
- Take the site universe from study_site, never from study_subject_visit. The visit table can only contain sites that have screened at least one subject, so a universe built from DISTINCT site_id there omits exactly the sites this metric exists to expose. Filter study_site to the study and to site_activation_date IS NOT NULL, then LEFT JOIN the per-site first randomization.
- Collapse the grain before aggregating anything on the visit side. The table repeats randomization_ts across every visit of a randomized subject, so any count taken at row grain is inflated by visits per subject. MIN(randomization_ts) per site is safe, COUNT is not.
- State the date boundary rule. randomization_ts is a timestamp and site_activation_date is a date, so a randomization at 23:40 local time can land on either side of a day boundary depending on the zone the timestamp is stored in. Cast once, deliberately, and say which zone.
- Use PERCENTILE_CONT(0.5) WITHIN GROUP (ORDER BY days) for the median and be explicit that it ignores NULLs, so it is a median over enrolling sites only. That is exactly why the non-enroller share is reported beside it rather than instead of it.
- Censor the day-90 denominator against the data cut. A site activated 40 days before the cut has not had 90 days to randomize, so it cannot be scored on that bar and belongs outside that denominator.
Worked solution 25 min
- CTE sites: site_id and site_activation_date from study_site for the study where site_activation_date IS NOT NULL. The (study_id, site_id) key already gives one activation date per site, so assert that key rather than de-duplicating defensively.
- CTE first_rand: site_id and MIN(randomization_ts) over study_subject_visit rows for the study where randomization_ts IS NOT NULL, grouped by site_id.
- LEFT JOIN sites to first_rand and compute days_to_first_randomization with an explicit cast of the timestamp to a date.
- Summary: PERCENTILE_CONT(0.5) over non-null days, plus the count and share of sites with no randomization by day 90, restricted to sites activated at least 90 days before the data cut.
- Compare the site-level row count with COUNT(DISTINCT site_id) in study_subject_visit for the study; the difference is the activated sites that have screened nobody, which is the population the metric is for.
Follow-up
- The same site_id appears under two studies. What breaks, and what is the correct grain for this metric?
- Would you present this as a median, as a Kaplan-Meier curve of time to first randomization, or both, and what does the curve show that the median cannot?
- A site randomized one subject who withdrew at visit 2. Does that site count as enrolling here, and how does that differ from a randomized-and-retained measure?
What key performance indicators would you establish to monitor the ope…
What key performance indicators would you establish to monitor the operational health and data freshness of an automated biomedical pipeline?
Approach
- State what result would change your recommendation, so the answer is falsifiable.
- Name one primary metric, then the guardrail that stops it being gamed.
- Decompose the metric into the rates that drive it, and say which one you would check first.
Follow-up
- How would you detect that the metric is being gamed rather than genuinely improving?
- What would you do if the primary metric and the guardrail moved in opposite directions?
How do you balance latency, computational cost, and retrieval accuracy…
How do you balance latency, computational cost, and retrieval accuracy when defining optimization targets for automated scientific reasoning tools?
Approach
- State what result would change your recommendation, so the answer is falsifiable.
- Decompose the metric into the rates that drive it, and say which one you would check first.
- Fix the population and the time window before naming any metric.
Follow-up
- How would you detect that the metric is being gamed rather than genuinely improving?
- Which segment would you cut first, and what would that rule out?
How would you design a core set of product metric design indicators to…
How would you design a core set of product metric design indicators to measure the reasoning efficiency and accuracy of a biological AI agent?
Approach
- Name one primary metric, then the guardrail that stops it being gamed.
- Restate the decision this analysis has to support, and who acts on the answer.
- Decompose the metric into the rates that drive it, and say which one you would check first.
Follow-up
- Which segment would you cut first, and what would that rule out?
- How would you detect that the metric is being gamed rather than genuinely improving?
Imagine a critical metric tracking successful context retrieval drops …
Imagine a critical metric tracking successful context retrieval drops by fifteen percent overnight. How would you approach this metric drop diagnosis step by step?
Approach
- State what result would change your recommendation, so the answer is falsifiable.
- Restate the decision this analysis has to support, and who acts on the answer.
- Decompose the metric into the rates that drive it, and say which one you would check first.
Follow-up
- What would you do if the primary metric and the guardrail moved in opposite directions?
- How would you detect that the metric is being gamed rather than genuinely improving?
How do you determine sample size and power when dealing with noisy, lo…
How do you determine sample size and power when dealing with noisy, low-throughput biological assay validation experiments?
Approach
- Name the guardrails that would stop a launch even on a positive primary result.
- Say whether units interfere with each other, and switch design if they do.
- Decide the analysis before seeing data, including how long it runs and when you look.
Follow-up
- What would you do if you could not randomise at all?
- What would you conclude if the result is positive but the test is underpowered?
How would you design an A/B testing framework to evaluate two differen…
How would you design an A/B testing framework to evaluate two different retrieval strategies in a biological knowledge retrieval system?
Approach
- Say whether units interfere with each other, and switch design if they do.
- State the primary metric and the minimum effect worth shipping, then size the test.
- Name the randomisation unit first; it decides the variance and what the test can detect.
Follow-up
- What would you do if you could not randomise at all?
- How would you handle interference between treated and control units?
Estimate a programme effect at a fixed risk-score enrolment cutoff
Care management enrols members whose prospective_risk_score in member_enrollment crosses a fixed annual threshold of 1.75; above the line enrolment is near-automatic and below it unavailable, and about 85 percent of members above the line actually enrol. Leadership refused a randomised holdout and wants the programme's effect on next-year allowed PMPM. Two years of scores and claims are available. State the design, the estimand it identifies, the assumptions, and the diagnostics you would run before reporting anything.
Approach
- Propose a fuzzy regression discontinuity on prospective_risk_score at 1.75. Uptake jumps but is not complete, so the estimator is the ratio of the jump in outcome to the jump in enrolment probability at the cutoff, which is a Wald ratio.
- State the estimand honestly up front: a local effect for members near 1.75, who are the least sick enrollees. It does not identify the effect on the top risk decile, which is usually the number leadership actually wants, and saying so before the result lands is what keeps the analysis credible.
- Say explicitly why the obvious alternative fails. A pre-post on enrolled members selects on a high score in year one, and such cohorts regress toward the mean in year two whether or not anything is done, so a pre-post design reports savings every time. The discontinuity is immune because it compares members on either side of an arbitrary line.
- Specify the estimation: local linear fits on each side, triangular kernel, a data-driven MSE-optimal bandwidth, and robust bias-corrected inference rather than a naive local-linear confidence interval. Do not fit a high-order global polynomial.
- Run the falsification suite before looking at the effect: a density test for manipulation of the running variable, continuity of pre-determined covariates at the cutoff, sensitivity across bandwidths, and placebo cutoffs away from 1.75.
Worked solution 30 min
- Plot the outcome and the enrolment rate against the centred running variable in uniform bins to confirm a visible jump in both.
- Estimate the first stage (jump in enrolment probability at 1.75) and the reduced form (jump in next-year PMPM), then take the ratio for the fuzzy RD estimate.
- Select the bandwidth by an MSE-optimal rule with a triangular kernel and local linear fits, and report robust bias-corrected intervals.
- Run the density test at 1.75 and the covariate continuity tests on age, prior-year cost, dual_eligible_flag, and product_type.
- Re-estimate at 0.5x, 1x, and 2x the selected bandwidth, and at placebo cutoffs of 1.50 and 2.00.
Follow-up
- Risk scores are built from coded diagnoses, and coding intensity is something people can influence. What would manipulation look like in the density, and what do you do if you see it?
- The MSE-optimal bandwidth leaves 900 members. How do you decide whether to report an underpowered estimate at all?
- Design an encouragement version instead: randomise the invitation rather than enrolment. What does instrumental variables buy you, and which assumption is most at risk?
Adherence share collapsed the month a feed was added
The share of members with proportion of days covered at or above 0.80 in one therapeutic class fell from 0.71 to 0.58 in a single month. pharmacy_claim carries fill_id, member_id, ndc_code, therapeutic_class_code, fill_date, days_supply, quantity_dispensed, refill_number, reversal_flag, reversed_fill_id and source_system_code. There is no person-level key above member_id and no enrollment table on hand, so every diagnostic has to run on pharmacy_claim alone. That month the pipeline began ingesting a second pharmacy source. Determine whether adherence actually changed, and hand back a PDC query you would defend line by line.
Approach
- Compute controls that depend on neither member identity nor the PDC code: total fills in the class per month, and total days_supply dispensed in the class per month. Both are sums over rows, so neither moves when one person's fills split across two member_ids, which is exactly what a per-member control cannot promise. If both are flat while PDC falls, no dispensing behaviour changed and the computation or the keys did.
- Check days_supply for nulls and zeros by source_system_code. If the new source omits days_supply and the code coalesces null to zero, covered days vanish and PDC falls even though the fills are there.
- Check for member identity splitting using the columns you actually have. There is no person key above member_id, so the split has to be found by its footprint: distinct member_id in the class jumping at the break while total fills stay flat, and a rise in the share of member_ids whose earliest fill for a given ndc_code carries refill_number above zero, which is a continuation history that lost its beginning. When one person is split, each id may fall below the two-fill denominator requirement and drop out, and the ids that do survive carry artificial gaps.
- Check reversals. A reversed fill is two rows, the fill and a row with reversal_flag TRUE pointing at reversed_fill_id, and both must be excluded from exposure. If the new source expresses reversals differently and reversed_fill_id does not link, phantom coverage appears, which pushes PDC up rather than down, so use this to rule the cause in or out.
- Verify the denominator and window are unchanged: members with at least two fills in the class and at least 91 days of follow-up, over a stated fixed 12-month window, never a mixture of window lengths.
- Write the PDC query so overlapping refills shift the next interval's start to the later of fill_date and the prior interval's end, so a day is covered at most once, and cap at one day per calendar day.
Follow-up
- Why is PDC preferred to medication possession ratio when early refills are common?
- You want to compare adherent and non-adherent members on hospitalisation. What is wrong with classifying on a 12-month PDC and then following from day zero?
- A member switches to a different drug in the same class mid-year. How does your interval logic handle that, and is the class the right grain?
Four days spend equal time on query work, statistics, modelling and product judgement at deliberately shallow depth, which produces a scored map of where you actually stand. The last three days spend everything on the two areas the role weights most, and close by re-running day one to measure movement.
Prepare, practise & reflect
One practical outcome each day. Spend longer where you need it.
0 / 7 done01Breadth pass: query fluency
- Solve six prompts spanning aggregation, joins, window functions and date arithmetic in 60 minutes total, stopping at 10 minutes each whether or not it works, and mark every prompt as solved, solved slowly, or stuck.
- For each unsolved prompt write the single blocking sentence (I lost the grain, I did not know the frame clause, I could not express the date boundary) instead of reading the solution.
- Translate one pandas transformation you know well into SQL and one SQL query into pandas, checking that both return the same row count and the same totals.
Deliverable: A scored six-row table, one line per prompt, saved for the day-seven re-run.
Practice prompt ↗Practice prompt ↗Practice prompt ↗Worked solution ↗02Breadth pass: statistics and inference
- Answer ten short questions in writing with nothing open: what a p-value is conditional on, what a 95 percent interval covers across repeated samples, when a paired test is the right one, what the bootstrap estimates, why multiple comparisons inflate false positives, how controlling the family-wise error rate differs from controlling the false discovery rate, what power depends on, what a missed real effect costs a product, the three situations where the central limit theorem does not rescue you (small n, very heavy tails, dependent observations), and what a standard error is the standard deviation of.
- Grade yourself against a reference and count only the answers that were exactly right, not the ones that were nearly right.
- Rewrite the two weakest answers the following morning from memory in full sentences.
Deliverable: Ten graded answers with an honest count of exact hits.
Practice prompt ↗Practice prompt ↗Practice prompt ↗03Breadth pass: modelling
- Take one tabular dataset end to end in 90 minutes: a leakage-safe split, a baseline that is not a model (majority class or historical mean), one regularized linear model, one gradient-boosted tree, and a single evaluation metric chosen before you look at any result.
- Write why that metric fits the cost structure: precision at a fixed recall for alerting, calibration for anything feeding a price or a threshold, ranking metrics for retrieval, and note that area under the ROC curve is insensitive to class balance in a way that can flatter a rare-positive problem.
- Name the leak you were most likely to introduce (an encoding fit on all rows before splitting, or a feature computed after the label's timestamp) and write the check that would have caught it.
Deliverable: A notebook whose first cell states the metric and the baseline, plus two lines on what beat what and by how much.
Practice prompt ↗Practice prompt ↗Practice prompt ↗04Breadth pass: product judgement
- Answer three case prompts aloud at 15 minutes each, timing how long passes before you state a success metric.
- For one case write the first segmentation you would run and the row counts you expect per segment, so that a tiny segment cannot quietly drive the conclusion.
- Take a metric definition you did not write, from a public dashboard, a textbook, or documentation you already have open, and list every place two analysts implementing it would diverge: which rows the denominator admits, whether the unit is an account or a person, what the time window is anchored to, and what happens to data that arrives late. Then write the one question that would close the largest of those gaps.
Deliverable: Three recorded case answers plus an ambiguity list for a metric someone else defined, ending in the single question you would ask about it.
Practice prompt ↗Practice prompt ↗Worked solution ↗05Depth, first area
- Rank the four areas by how many bullet points in the role description each one covers, pick the top one, and spend the entire day inside it.
- Work the six hardest problems you can find in that area and for each write the generalizable move you should have reached for first, rather than the answer.
- Re-solve the two you failed the same evening with notes closed.
Deliverable: Six generalizable moves written as instructions to yourself, not as solutions.
Practice prompt ↗Practice prompt ↗06Depth, second area, and the seam between them
- Repeat the depth protocol on the second-ranked area with the same six-problem structure.
- Construct one problem that requires both areas at once, for example a metric redefinition whose effect you must validate with a test whose readout you then have to query.
- Solve your own combined problem end to end and note where the handoff between the two areas cost you time.
Deliverable: One combined problem, solved end to end, with the handoff failure written down.
Practice prompt ↗Practice prompt ↗07Integration and re-measurement
- Re-run the six prompts from day one under the same clock and compare both correctness and time.
- Run a 60-minute mixed mock that moves between areas without warning, since switching cost is what breadth passes do not train.
- Write the two areas you would still fail on, and the sentence you will use in the interview when you hit one of them.
Deliverable: A before-and-after score table plus a written plan for the two remaining gaps.
Practice prompt ↗Practice prompt ↗Worked solution ↗Expand any day for tasks and deliverables. Your progress is saved on this device.
Most data work is done by groups, so an interviewer has to work out which piece was yours. An answer that runs on 'we' for several minutes gets interrupted with a question about what you personally did, and by then the answer sounds defensive even when it is true. Mark your own contribution as you go, and name the parts that belonged to someone else instead of leaving them ambiguous. Keep a few specifics back as well, like the name of the metric or who actually objected, so a probe can be answered with something you had not already said.
How do you handle disagreements within a cross-functional team regardi…
How do you handle disagreements within a cross-functional team regarding architectural direction or feature prioritization?
Approach
- Quantify the outcome, including what you would not claim credit for.
- Close with what you would do differently, concretely.
- Pick a story where you drove the decision, not one where you observed it.
Follow-up
- How did you know the outcome was caused by your change?
- What did you decide not to do, and why?
Explain an incomplete cost series to a non-technical executive
An executive opens a dashboard showing risk-adjusted allowed PMPM down 6 percent across the last three incurred months and asks whether the cost initiative is working. You know pharmacy adjudicates within days, professional claims within weeks, and inpatient facility claims over months, so those three months are both undercounted and mix-shifted toward cheap services. There is also a genuine movement of roughly 1.5 percent in the older, complete months. Deliverable: a two-minute spoken answer, the change you make to the chart, and what you commit to telling them and when.
Approach
- The probe is whether you can be honest about uncertainty without sounding evasive. Executives read hedging as not knowing, so the answer has to end in a commitment.
- Separate the two claims immediately. The 6 percent is an artefact of incomplete data, and there is a smaller real movement in the months that are complete. Delivering only the debunk leaves them holding nothing.
- Explain the lag in their terms: the bills for the most expensive care arrive last, so an incomplete month always looks cheap and always looks like it is improving. Keep the phrase completion factor out of the first pass.
- Fix the chart instead of explaining around it. Shade or omit the incomplete months, print the paid-through date on the axis, and overlay the same series as it looked at equivalent maturity a year earlier so the shape is comparable rather than merely lower.
- Close with a date and a magnitude. Commit to a restated figure once runout matures, say roughly how far you expect the 6 percent to shrink, and name what you would need to see to call the initiative working.
Follow-up
- They ask for your best guess today, knowing it is provisional. What do you say?
- The restated number comes back at 1 percent. How do you handle having flagged the 6 percent at all?
- How do you stop this dashboard producing the same conversation next quarter?
Own an analysis that shipped wrong and was acted on
Describe an analysis you delivered that was wrong, where someone acted on it before the error surfaced. Pick something with a mechanism you can name, not a typo. Cover what the number claimed, what was actually true, how much time passed before it was caught, who caught it, and what you told the people who had already acted. Deliverable: a five-minute account that ends with the specific control you added afterwards, plus one occasion since when that control has fired.
Approach
- Read the probe: the interviewer is testing whether you detect your own errors and whether the correction was structural. Pick an error with a nameable mechanism (a denominator built from distinct members instead of member-months, a series read before claims runout completed, a cohort selected on the outcome) so the story has a diagnosis rather than a mood.
- Open with the decision that was made on your number, not with the bug. The severity of an analytic error is measured in the action it caused: a rate filing, a staffing plan, a programme expansion.
- State the counterfactual number. 'The true figure was 14.1 admissions per 1,000 member-years, not 9.8' is a fact; 'it was off by a lot' is not.
- Describe the detection path honestly, including whether you found it or somebody else did. Say how long it took, because time to detection is the part you actually control next time.
- Close on the control, and make it something that protects a reader who has never met you: a unit test on the denominator, a paid-through date stamped on every chart, a required exclusions block in the spec template. Name one later date it caught something.
Follow-up
- What would have had to be true for you to catch this before delivery rather than after?
- Did the stakeholder change how much they trust your work, and did you want them to?
- Give an example of a control you added that turned out to be the wrong control.
- 01
How do you handle disagreements within a cross-functional team regarding architectural direction or feature prioritization?
- 02
An executive opens a dashboard showing risk-adjusted allowed PMPM down 6 percent across the last three incurred months and asks whether the cost initiative is working. You know pharmacy adjudicates within days, professional claims within weeks, and inpatient facility claims over months, so those three months are both undercounted and mix-shifted toward cheap services. There is also a genuine movement of roughly 1.5 percent in the older, complete months. Deliverable: a two-minute spoken answer, the change you make to the chart, and what you commit to telling them and when.
- 03
Describe an analysis you delivered that was wrong, where someone acted on it before the error surfaced. Pick something with a mechanism you can name, not a typo. Cover what the number claimed, what was actually true, how much time passed before it was caught, who caught it, and what you told the people who had already acted. Deliverable: a five-minute account that ends with the specific control you added afterwards, plus one occasion since when that control has fired.
Is this an official Recursion Pharmaceuticals interview guide?
No. It is PracHub's own research and practice material for the Data Scientist role at Recursion Pharmaceuticals. Rounds and questions reflect what candidates have reported, not a process Recursion Pharmaceuticals has published, and they change over time. Confirm the current format and scope with your recruiter.
PracHub interview research ↗How difficult is the interview loop, and how much preparation time should I plan for?
The interview process is rigorous and multi-staged, reflecting the high technical bar at Recursion Pharmaceuticals. Candidates typically spend several weeks reviewing core statistical concepts, practicing SQL and coding assessments, and structuring examples from their past projects.
PracHub interview research ↗What differentiates successful candidates from those who do not pass?
Successful candidates combine deep technical competence with a pragmatic understanding of biological data complexity. They excel at communicating their architectural decisions clearly, demonstrating both scientific curiosity and strong software engineering discipline.
PracHub interview research ↗What is the company culture like for data scientists?
The culture emphasizes bold thinking, active experimentation, and radical cross-functional collaboration. Teams move with urgency because patients are waiting, fostering an environment where accountability and direct engagement are paramount.
PracHub interview research ↗What is the typical timeline from initial screen to offer?
The timeline can vary depending on team scheduling and the thoroughness of the evaluation stages, often spanning several weeks from the initial recruiter chat through the final panel loop and work sample review.
PracHub interview research ↗Sources & methodology 3 sources ↗
No official company page is cited. Rounds and questions come from candidate reports and PracHub editorial material; each source shows the date it was read.
- 01PracHub interview research ↗
PracHub editorial research into this company and role, maintained with this guide. Candidate-reported, not an employer publication.
PracHub page · Accessed 2026-09-22 - 02PracHub Data Scientist practice ↗
Cross-company practice questions for this role.
PracHub page · Accessed 2026-09-22 - 03PracHub interview preparation framework ↗
The framework the preparation plan follows.
PracHub page · Accessed 2026-09-22
Explore related engineering environments and compare the preparation focus.
Veracyte Data Scientist Interview Questions & Guide 2026
Causal-inference exercises for Veracyte data scientist prep: difference-in-differences, matching, instrumental variables, and knowing when observational data simply cannot answer the question asked.
Zoetis Data Scientist Interview Questions & Guide 2026
Metric-diagnosis practice for Zoetis data scientist candidates: a number moves week over week and you work out why, splitting by segment, ruling out a logging or release change, and separating a mix shift from a real change in user behaviou
Vizient Data Scientist Interview Questions & Guide 2026
Communication practice for Vizient data scientist candidates: turn an analysis into a recommendation, name the uncertainty honestly, and answer the follow-up a skeptical stakeholder will raise.
Vibrant Emotional Health Data Scientist Interview Questions & Guide 2026
Case practice for the Vibrant Emotional Health data scientist interview, where the prompt is deliberately underspecified and your first move is scoping it into something measurable.